Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies

Medicine and Dentistry

• Epidermal Growth Factor Receptor Kinase Inhibitor 100%
• Combination Therapy 66%
• Tyrosine-Kinase Inhibitor 66%
• Epidermal Growth Factor Receptor 50%
• Non Small Cell Lung Cancer 50%
• Patient 50%
• Biological Marker 33%
• Randomized Clinical Trial 33%
• Targeted Therapy 33%
• Therapeutic Procedure 33%
• In Vitro 16%
• Pharmacokinetics 16%
• Neoplasm 16%
• Diseases 16%
• Disease Exacerbation 16%
• Receptor 16%
• Immunotherapy 16%
• Receptor Gene 16%
• Threonine 16%
• Translational Research 16%
• Liquid Biopsy 16%
• Chemotherapeutic Agent 16%
• Development 16%
• Platinum 16%
• Drug 16%
• Cancer Therapy 16%
• Methionine 16%
• Osimertinib 16%
• Monitoring 16%
• Assessment 16%
• Position 16%
• Ethinylestradiol Plus Megestrol Acetate 16%
• Mutant 16%
• Selectivity 16%
• Evolution 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Epidermal Growth Factor Receptor Kinase Inhibitor 100%
• Protein Tyrosine Kinase Inhibitor 66%
• Non Small Cell Lung Cancer 50%
• Epidermal Growth Factor Receptor 50%
• Biological Marker 33%
• Cytotoxic Chemotherapy 33%
• Chemotherapy 33%
• Clinical Research 33%
• Pharmacokinetics 16%
• Diseases 16%
• Neoplasm 16%
• Disease Exacerbation 16%
• Immunotherapy 16%
• Receptor 16%
• Platinum 16%
• Methionine 16%
• Threonine 16%
• Drug 16%
• Osimertinib 16%
• Ethinylestradiol Plus Megestrol Acetate 16%